StockMacro
Menu

Guardant Health

$145.83 +22% in 6 monthsMarket cap $19.7B

GH on XNAS, Health Care, Guardant Health, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue up 42% to $1.3B over 12 months but net loss was $485.1M.

  • GoodInstitutional holders up 14%, from 585 to 668 last quarter
  • BadFree cash flow was -$232.1M over 12 months

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Industry
Services-medical laboratories (Health Care)
Employees
2,506
Website
guardanthealth.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $361.0M, net loss $124.4M.
Quarter to 31 Dec 2021: revenue $108.1M, net income -$72.3MQuarter to 31 Dec 2021: revenue $108.1M, net income -$72.3MQuarter to 31 Mar 2022: revenue $96.1M, net income -$123.2MQuarter to 31 Mar 2022: revenue $96.1M, net income -$123.2MQuarter to 30 Jun 2022: revenue $109.1M, net income -$229.4MQuarter to 30 Jun 2022: revenue $109.1M, net income -$229.4MQuarter to 30 Sep 2022: revenue $117.4M, net income -$162.0MQuarter to 30 Sep 2022: revenue $117.4M, net income -$162.0MQuarter to 31 Dec 2022: revenue $126.9M, net income -$139.9MQuarter to 31 Dec 2022: revenue $126.9M, net income -$139.9MQuarter to 31 Mar 2023: revenue $128.7M, net income -$133.5MQuarter to 31 Mar 2023: revenue $128.7M, net income -$133.5MQuarter to 30 Jun 2023: revenue $137.2M, net income -$72.8MQuarter to 30 Jun 2023: revenue $137.2M, net income -$72.8MQuarter to 30 Sep 2023: revenue $143.0M, net income -$86.1MQuarter to 30 Sep 2023: revenue $143.0M, net income -$86.1MQuarter to 31 Dec 2023: revenue $155.1M, net income -$187.0MQuarter to 31 Dec 2023: revenue $155.1M, net income -$187.0MQuarter to 31 Mar 2024: revenue $168.5M, net income -$115.0MQuarter to 31 Mar 2024: revenue $168.5M, net income -$115.0MQuarter to 30 Jun 2024: revenue $177.2M, net income -$102.6MQuarter to 30 Jun 2024: revenue $177.2M, net income -$102.6MQuarter to 30 Sep 2024: revenue $191.5M, net income -$107.8MQuarter to 30 Sep 2024: revenue $191.5M, net income -$107.8MQuarter to 31 Dec 2024: revenue $201.8M, net income -$111.0MQuarter to 31 Dec 2024: revenue $201.8M, net income -$111.0MQuarter to 31 Mar 2025: revenue $203.5M, net income -$95.2MQuarter to 31 Mar 2025: revenue $203.5M, net income -$95.2MQuarter to 30 Jun 2025: revenue $232.1M, net income -$99.9MQuarter to 30 Jun 2025: revenue $232.1M, net income -$99.9MQuarter to 30 Sep 2025: revenue $265.2M, net income -$92.7MQuarter to 30 Sep 2025: revenue $265.2M, net income -$92.7MQuarter to 31 Dec 2025: revenue $281.3M, net income -$128.5MQuarter to 31 Dec 2025: revenue $281.3M, net income -$128.5MQuarter to 31 Mar 2026: revenue $301.7M, net income -$112.1MQuarter to 31 Mar 2026: revenue $301.7M, net income -$112.1MQuarter to 30 Jun 2026: revenue $335.0M, net income -$120.1MQuarter to 30 Jun 2026: revenue $335.0M, net income -$120.1MQuarter to 30 Sep 2026: revenue $361.0M, net income -$124.4MQuarter to 30 Sep 2026: revenue $361.0M, net income -$124.4M
31 Dec 2021RevenueNet incomeNet losstallest bar $361.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$361.0M-$124.4M
30 Jun 2026$335.0M-$120.1M
31 Mar 2026$301.7M-$112.1M
31 Dec 2025$281.3M-$128.5M
30 Sep 2025$265.2M-$92.7M
30 Jun 2025$232.1M-$99.9M
31 Mar 2025$203.5M-$95.2M
31 Dec 2024$201.8M-$111.0M
30 Sep 2024$191.5M-$107.8M
30 Jun 2024$177.2M-$102.6M
31 Mar 2024$168.5M-$115.0M
31 Dec 2023$155.1M-$187.0M
30 Sep 2023$143.0M-$86.1M
30 Jun 2023$137.2M-$72.8M
31 Mar 2023$128.7M-$133.5M
31 Dec 2022$126.9M-$139.9M
30 Sep 2022$117.4M-$162.0M
30 Jun 2022$109.1M-$229.4M
31 Mar 2022$96.1M-$123.2M
31 Dec 2021$108.1M-$72.3M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.3B $902.6M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +42% +17%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$485.1M -$398.8M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$3.68 -$3.21
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 65.2% 63.8% 33.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -39.4% -49.0% -8.2%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -37.9% -44.2% -5.9%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -10.1%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$232.1M -$262.2M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $1.0B $580.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $1.5B $1.1B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $475.6M $534.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.16
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 29.1
P/SPrice to sales: market cap divided by revenue of the last 12 months. 15.4 3.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 15.8 2.6
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Guardant HealthGH (this company) $19.7Bloss15.4+42%-37.9%
Quest DiagnosticsDGX $28.4B25.22.4+9.1%9.5%
LabcorpLH $29.8B29.72.0+6.0%6.9%
NateraNTRA $39.6Bloss13.6+37%-5.7%
RadNetRDNT $5.5Bloss2.3+21%-0.9%
Caris Life SciencesCAI $5.0B52.54.8+61%9.2%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$10.3M

bought $0, sold $10.3M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+14%

668 13F filers vs 585

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

98%

132.9M shares held by 13F filers (30 Sep 2026) of 135.3M outstanding (30 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

7.0%

9.4M shares sold short (30 Oct 2026) of 135.3M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

5.4

9.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-19%

11.7M shares sold short in the report before, 9.4M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

41%

41% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 49%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-22%

28 vs 36 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+36%

$361.0M vs $265.2M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+30%

$13.5M vs $10.3M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$1.3M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

34

34 articles in the last 7 days; its usual week has 6 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

5.7×

34 articles in the last 7 days; its usual week has 6.

Price $145.83 on 20 Nov 2026, +45% over 12 months (12-month range $78.60 to $187.22)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $173.4M in the last 12 months (the 12 months before: -$37.4M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 28 published in the last 12 months, -22% on the 12 months before.
Revenue per quarter. Revenue $361.0M in the latest quarter, +36% on a year earlier.
Capital spending per quarter. Capital spending $13.5M in the latest quarter, +30% on a year earlier.
Institutional holders (13F filers). 668 13F filers reported holding it in the latest 13F quarter, +83% on a year earlier.
Lobbying spend. Lobbying spend: $1.3M published in the last 12 months, +37% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
3 Nov 20268-K and other filingsDirector or officer change
3 Nov 20268-K and other filingsDirector or officer change
3 Nov 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Oct 2026Lobbying filinglobbying engagement terminated (TODD STRATEGY GROUP)
4 Aug 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 11.8M vs usual 5.6M (2026-06-30); 2.1x the same period a year earlier
27 Apr 20268-K and other filingsDirector or officer change
27 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Apr 2026Sharp changeLobbying on a new issue: lobbying on a new issue: MED (2026-03-31)
14 Apr 2026Sharp changeShort interest spike: short interest spike, 13.7M vs usual 9.2M (2026-03-31); 1.7x the same period a year earlier
19 Mar 2026Lobbying filinglobbying engagement terminated (DC STRATEGISTS LLC)
30 Oct 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 10.3M vs usual 4.8M (2025-09-30); 2.5x the same period a year earlier
19 Oct 2025Lobbying filingnew lobbying registration (DC STRATEGISTS LLC)
12 Oct 2025Lobbying filingnew lobbying registration (TODD STRATEGY GROUP)
15 Sep 20258-K and other filingsDirector or officer change
15 Sep 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Jul 2025Lobbying filinglobbying engagement terminated (MANATT, PHELPS, AND PHILLIPS)
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 84 vs usual 39 (2025-03-31); 2.3x the same period a year earlier
25 Feb 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 18.9M vs usual 5.8M (2024-12-31); 4.6x the same period a year earlier
24 Oct 20248-K and other filingsDirector or officer change
24 Oct 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Jul 20248-K and other filingsDirector or officer change
3 Jul 2024Lobbying filinglobbying engagement terminated (INVARIANT LLC)
31 May 20248-K and other filingsDirector or officer change
28 May 2024Sharp changeShort interest spike: short interest spike, 10.8M vs usual 7.0M (2024-05-15); 1.5x the same period a year earlier
30 Apr 2024Lobbying filingnew lobbying registration (MANATT, PHELPS, AND PHILLIPS)
22 Mar 20248-K and other filingsDirector or officer change
1 Feb 20248-K and other filingsDirector or officer change
1 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Nov 20238-K and other filingsDirector or officer change
3 Nov 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Jun 2023Sharp changeShort interest spike: short interest spike, 6.9M vs usual 4.4M (2023-05-31); 1.7x the same period a year earlier
30 May 2023Sharp changeShort interest spike: short interest spike, 7.1M vs usual 4.3M (2023-05-15); 2.1x the same period a year earlier
16 May 2023Sharp changeShort interest spike: short interest spike, 6.4M vs usual 4.3M (2023-04-28); 1.6x the same period a year earlier
8 May 20238-K and other filingsDirector or officer change
2 May 2023Sharp changeShort interest spike: short interest spike, 7.0M vs usual 4.3M (2023-04-14); 1.8x the same period a year earlier
18 Apr 2023Sharp changeShort interest spike: short interest spike, 6.8M vs usual 4.2M (2023-03-31); 1.8x the same period a year earlier
18 Apr 2023Lobbying filinglobbying engagement terminated (POWERS PYLES SUTTER & VERVILLE, P.C.)
10 Apr 20238-K and other filingsChanged its auditor
28 Mar 2023Sharp changeShort interest spike: short interest spike, 6.3M vs usual 4.2M (2023-03-15); 1.7x the same period a year earlier
14 Mar 2023Sharp changeShort interest spike: short interest spike, 7.0M vs usual 4.1M (2023-02-28); 1.8x the same period a year earlier
28 Feb 2023Sharp changeShort interest spike: short interest spike, 6.2M vs usual 4.0M (2023-02-15); 1.8x the same period a year earlier
27 Feb 20238-K and other filingsDirector or officer change
27 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Feb 2023Sharp changeShort interest spike: short interest spike, 5.5M vs usual 4.0M (2023-01-31); 1.4x the same period a year earlier
3 Feb 2023Lobbying filingnew lobbying registration (IPOLICY SOLUTIONS)
31 Jan 2023Sharp changeShort interest spike: short interest spike, 5.6M vs usual 4.0M (2023-01-13); 1.3x the same period a year earlier
20 Jul 2022Sharp changeLobbying on a new issue: lobbying on a new issue: LBR (2022-06-30)
7 Jul 20228-K and other filingsDirector or officer change
13 Jun 20228-K and other filingsA major agreement ended
10 May 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 22.7M vs usual 9.7M (2022-03-31); 2.4x the same period a year earlier
5 May 20228-K and other filingsDirector or officer change
1 Mar 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 24.6M vs usual 9.6M (2021-12-31); 3.4x the same period a year earlier
28 Feb 20228-K and other filingsDirector or officer change
28 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Jan 2022Lobbying filingnew lobbying registration (INVARIANT LLC)
18 Jan 2022Lobbying filinglobbying engagement terminated (CASSIDY & ASSOCIATES, INC.)
Insider net buying (open market)
Month from 1 Nov 2021: $20.1M published
Month from 1 Dec 2021: -$472K published
Month from 1 Jan 2022: -$425K published
Month from 1 Feb 2022: -$364K published
Month from 1 Mar 2022: -$290K published
Month from 1 Aug 2022: -$587K published
Month from 1 Nov 2022: -$162K published
Month from 1 Mar 2023: $4.7M published
Month from 1 Jun 2023: -$6K published
Month from 1 Sep 2023: -$73K published
Month from 1 Dec 2023: -$156K published
Month from 1 Mar 2024: $37K published
Month from 1 Jun 2024: -$3K published
Month from 1 Nov 2024: -$536K published
Month from 1 Dec 2024: -$89K published
Month from 1 Jan 2025: -$4K published
Month from 1 Feb 2025: -$6K published
Month from 1 Mar 2025: -$160K published
Month from 1 Apr 2025: -$5K published
Month from 1 May 2025: -$5.9M published
Month from 1 Jun 2025: -$6.9M published
Month from 1 Jul 2025: -$5.1M published
Month from 1 Aug 2025: -$132K published
Month from 1 Sep 2025: -$18.0M published
Month from 1 Oct 2025: -$10K published
Month from 1 Nov 2025: -$1.0M published
Month from 1 Dec 2025: -$43.7M published
Month from 1 Jan 2026: -$2.1M published
Month from 1 Mar 2026: -$4.2M published
Month from 1 Apr 2026: -$365K published
Month from 1 May 2026: -$35.4M published
Month from 1 Jun 2026: -$17.0M published
Month from 1 Jul 2026: -$39.4M published
Month from 1 Aug 2026: -$27.3M published
Month from 1 Sep 2026: -$3.3M published
Month from 1 Oct 2026: -$30K published
Month from 1 Nov 2026: -$575K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 17 published
Quarter from 1 Apr 2022: 12 published
Quarter from 1 Jul 2022: 25 published
Quarter from 1 Oct 2022: 10 published
Quarter from 1 Jan 2023: 4 published
Quarter from 1 Apr 2023: 5 published
Quarter from 1 Jul 2023: 9 published
Quarter from 1 Oct 2023: 12 published
Quarter from 1 Jan 2024: 8 published
Quarter from 1 Apr 2024: 10 published
Quarter from 1 Jul 2024: 16 published
Quarter from 1 Oct 2024: 11 published
Quarter from 1 Jan 2025: 10 published
Quarter from 1 Apr 2025: 6 published
Quarter from 1 Jul 2025: 13 published
Quarter from 1 Oct 2025: 7 published
Quarter from 1 Jan 2026: 8 published
Quarter from 1 Apr 2026: 9 published
Quarter from 1 Jul 2026: 9 published
Quarter from 1 Oct 2026: 2 published
Revenue per quarter
Quarter ended 31 Dec 2021: $108.1M, +38% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $96.1M, +22% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $109.1M, +19% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $117.4M, +24% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $126.9M, +17% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $128.7M, +34% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $137.2M, +26% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $143.0M, +22% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $155.1M, +22% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $168.5M, +31% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $177.2M, +29% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $191.5M, +34% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $201.8M, +30% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $203.5M, +21% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $232.1M, +31% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $265.2M, +39% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $281.3M, +39% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $301.7M, +48% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $335.0M, +44% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $361.0M, +36% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $24.6M, +238% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $22.7M, +137% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $23.0M, +23% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $21.7M, -1.9% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $10.0M, -59% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $7.5M, -67% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $6.5M, -72% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $2.4M, -89% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $4.1M, -59% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $6.9M, -7.8% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $5.1M, -22% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $4.2M, +77% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $18.9M, +363% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $4.5M, -36% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $5.6M, +11% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $10.3M, +146% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $27.8M, +48% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $5.6M, +25% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $11.8M, +108% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $13.5M, +30% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 360; public on 14 Feb 2022
31 Mar 2022 report: 332; public on 16 May 2022
30 Jun 2022 report: 309; public on 15 Aug 2022
30 Sep 2022 report: 302; public on 14 Nov 2022
31 Dec 2022 report: 265; public on 14 Feb 2023
31 Mar 2023 report: 255; public on 15 May 2023
30 Jun 2023 report: 273; public on 14 Aug 2023
30 Sep 2023 report: 270; public on 14 Nov 2023
31 Dec 2023 report: 275; public on 14 Feb 2024
31 Mar 2024 report: 237; public on 15 May 2024
30 Jun 2024 report: 263; public on 14 Aug 2024
30 Sep 2024 report: 255; public on 14 Nov 2024
31 Dec 2024 report: 290; public on 14 Feb 2025
31 Mar 2025 report: 326; public on 15 May 2025
30 Jun 2025 report: 353; public on 14 Aug 2025
30 Sep 2025 report: 365; public on 14 Nov 2025
31 Dec 2025 report: 478; public on 17 Feb 2026
31 Mar 2026 report: 473; public on 15 May 2026
30 Jun 2026 report: 585; public on 14 Aug 2026
30 Sep 2026 report: 668; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $200K published
Quarter from 1 Apr 2022: $220K published
Quarter from 1 Jul 2022: $220K published
Quarter from 1 Oct 2022: $220K published
Quarter from 1 Jan 2023: $220K published
Quarter from 1 Apr 2023: $260K published
Quarter from 1 Jul 2023: $260K published
Quarter from 1 Oct 2023: $260K published
Quarter from 1 Jan 2024: $260K published
Quarter from 1 Jul 2024: $520K published
Quarter from 1 Oct 2024: $260K published
Quarter from 1 Jan 2025: $260K published
Quarter from 1 Apr 2025: $241K published
Quarter from 1 Oct 2025: $482K published
Quarter from 1 Jan 2026: $741K published
Quarter from 1 Apr 2026: $241K published
Quarter from 1 Jul 2026: $180K published
Quarter from 1 Oct 2026: $180K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is lobbying spend reported (quarter) at $180K (30 Sep 2026), 25% below its normal reading of $241K; higher than 48% of its own history.
  • Quarterly capital spending jump: spent $11.8M on capital projects in the quarter ended 30 Jun 2026, 2.1× the same quarter last year Public on 4 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $173.4M in the last 12 months (the 12 months before: -$37.4M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 28 published in the last 12 months, -22% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 10 sales, $4.0M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Nov 2026Terilyn J. MonroeChief People OfficerSellplanned in advance (10b5-1)3,842$142.41$547KForm 4
17 Nov 2026Alex M Azar IIDirectorSellplanned in advance (10b5-1)69$149.56$10KForm 4
17 Nov 2026Musa TariqDirectorSellplanned in advance (10b5-1); after exercising options116$149.56$17KForm 4
19 Oct 2026Musa TariqDirectorSellplanned in advance (10b5-1); after exercising options116$165.88$19KForm 4
15 Oct 2026Alex M Azar IIDirectorSellplanned in advance (10b5-1)69$159.89$11KForm 4
17 Sep 2026Musa TariqDirectorSellplanned in advance (10b5-1); after exercising options116$175.00$20KForm 4
17 Sep 2026Steve E. KrognesDirectorSell6,674$175.74$1.2MForm 4
17 Sep 2026Darya ChudovaChief Technology OfficerSell7,738$178.00$1.4MForm 4

668 institutions reported shares at the end of Q3 2026, 98% of the shares outstanding; 133 opened a position, 58 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.8.0M5.92%$1.4B+380K+5.0%
FMR LLC (Fidelity)7.3M5.43%$1.3B+1.9M+34%
Vanguard Capital Management LLC5.8M4.29%$1.0B+52K+0.9%
T. Rowe Price Associates Inc5.7M4.23%-786K-12%
Vanguard Portfolio Management LLC5.3M3.94%$951.6M-111K-2.0%
Franklin Templeton Inc3.4M2.51%$571.8M+156K+4.8%
Two Sigma Investments, LP3.1M2.26%$546.4M-656K-18%
Invesco Ltd.3.0M2.20%$530.5M-1.5M-33%
Capital International Investors2.9M2.17%$523.8M-463K-14%
Deep Track Capital, LP2.8M2.07%$500.4M-588K-17%

Company events

All 43 company events

In 12 months: 3 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
16 Nov 2026Completed $550M 0% Convertible Senior Notes due 2032 offering, including full exercise of $50M option; indenture with U.S. Bank Trust Company as trusteeSame filing: took on new debt, sold shares privately8-K
3 Nov 2026Director or officer change8-K
3 Nov 2026Director or officer change8-K
27 Apr 2026Director or officer change8-K
7 Nov 2025Signed a major agreementSame filing: took on new debt, sold shares privately8-K
15 Sep 2025Director or officer change8-K
9 Apr 2025Signed a major agreementSame filing: took on new debt8-K
14 Feb 2025Signed a major agreementSame filing: took on new debt, sold shares privately8-K

Reported lobbying spend: $180K in Q3 2026, $180K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Jun 2026EndedTodd Strategy Groupfor Guardant Health, Inc.Cancer screening access. Precision diagnostics, cancer care and preventive screening innovation.Health issuesFiling
19 Mar 2026EndedDC Strategists LLCfor Guardant HealthNot statedFiling
4 Sep 2025NewDC Strategists LLCfor Guardant HealthMatters related to cancer screeningHealth issuesFiling
30 Jun 2025EndedManatt, Phelps, And Phillipsfor Guardant HealthAppropriations and HealthcareHealth issues, BudgetFiling
1 Apr 2025NewTodd Strategy Groupfor Guardant Health, Inc.Cancer screening access.Health issuesFiling
19 Apr 2024NewManatt, Phelps, And Phillipsfor Guardant HealthAppropriations and HealthcareHealth issues, BudgetFiling
1 Apr 2024EndedInvariant LLCfor Guardant Health, Inc.Not statedFiling
2 Jan 2023EndedPowers Pyles Sutter & Verville, P.C.for Guardant Health, Inc.Not statedFiling

The 5 newest of 321 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

20 Apr 2026confirmed

Confirmed across sources Lobbying and Short interest and volume

Guardant Health (GH): had 13.7M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 5 days.

  • Short interest and volume: Short interest spike, became public on 11 Apr 2026
  • Lobbying: Lobbying on a new issue, became public on 20 Apr 2026
2025-03-31: 8.3M2025-04-15: 7.6M2025-04-30: 7.7M2025-05-15: 9.1M2025-05-30: 8.9M2025-06-13: 10.0M2025-06-30: 9.4M2025-07-15: 9.6M2025-07-31: 9.4M2025-08-15: 8.2M2025-08-29: 8.0M2025-09-15: 8.7M2025-09-30: 8.3M2025-10-15: 8.3M2025-10-31: 8.4M2025-11-14: 9.0M2025-11-28: 9.2M2025-12-15: 9.9M2025-12-31: 10.4M2026-01-15: 9.8M2026-01-30: 9.5M2026-02-13: 10.5M2026-02-27: 11.0M2026-03-13: 11.5M2026-03-31: 13.7M
The 31 Mar 2026 report against the 24 reports before it. this reportearliernormal: 9.2M
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 11 Apr 2026

Guardant Health had 13.7M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.

This period
13.7M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
9.2M
Typical spread (median absolute deviation)
791K
How far from its usual level
+3.8
Same report last year
8.3M
History used
2,724 days
2025-03-31: 8.3M2025-04-15: 7.6M2025-04-30: 7.7M2025-05-15: 9.1M2025-05-30: 8.9M2025-06-13: 10.0M2025-06-30: 9.4M2025-07-15: 9.6M2025-07-31: 9.4M2025-08-15: 8.2M2025-08-29: 8.0M2025-09-15: 8.7M2025-09-30: 8.3M2025-10-15: 8.3M2025-10-31: 8.4M2025-11-14: 9.0M2025-11-28: 9.2M2025-12-15: 9.9M2025-12-31: 10.4M2026-01-15: 9.8M2026-01-30: 9.5M2026-02-13: 10.5M2026-02-27: 11.0M2026-03-13: 11.5M2026-03-31: 13.7M
the 31 Mar 2026 report24 earlier reportsnormal: 9.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Lobbying: Lobbying on a new issue became public on 20 Apr 2026

Guardant Health lobbying on a new issue.

New
['MED']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4686435

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 3 Nov 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 3 Nov 2026Filings record

    Director or officer change

  3. 3 Nov 2026Filings record

    Director or officer change

  4. 23 Oct 2026Lobbying record

    GUARDANT HEALTH, INC.: lobbying engagement terminated (TODD STRATEGY GROUP) (dated 30 Jun 2026)

  5. 4 Aug 2026Financials change

    spent $11.8M on capital projects in the quarter ended 30 Jun 2026, 2.1× the same quarter last year.

    Same quarter last year: $5.6M; its normal quarter is $5.6M.

    See the evidence
    This period
    $11.8M (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $5.6M
    Typical spread (median absolute deviation)
    $1.3M
    How far from its usual level
    +3.2
    Same quarter last year
    $5.6M
    History used
    3,103 days
    2024-06-30: $5.1M2024-09-30: $4.2M2024-12-31: $18.9M2025-03-31: $4.5M2025-06-30: $5.6M2025-09-30: $10.3M2025-12-31: $27.8M2026-03-31: $5.6M2026-06-30: $11.8M
    the quarter ended 30 Jun 20268 earlier quartersnormal: $5.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  6. 1 Jul 2026Insiders record

    Kalia Kumud (Chief Information Officer) bought 600 shares of GH ($78,456) (dated 30 Jun 2026)

  7. 27 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 27 Apr 2026Filings record

    Director or officer change

  9. 20 Apr 2026several at once

    had 13.7M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 5 days.

    See the evidence (2 changes)

    Short interest and volume: Short interest spike became public on 11 Apr 2026

    Guardant Health had 13.7M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.

    This period
    13.7M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    9.2M
    Typical spread (median absolute deviation)
    791K
    How far from its usual level
    +3.8
    Same report last year
    8.3M
    History used
    2,724 days
    2025-03-31: 8.3M2025-04-15: 7.6M2025-04-30: 7.7M2025-05-15: 9.1M2025-05-30: 8.9M2025-06-13: 10.0M2025-06-30: 9.4M2025-07-15: 9.6M2025-07-31: 9.4M2025-08-15: 8.2M2025-08-29: 8.0M2025-09-15: 8.7M2025-09-30: 8.3M2025-10-15: 8.3M2025-10-31: 8.4M2025-11-14: 9.0M2025-11-28: 9.2M2025-12-15: 9.9M2025-12-31: 10.4M2026-01-15: 9.8M2026-01-30: 9.5M2026-02-13: 10.5M2026-02-27: 11.0M2026-03-13: 11.5M2026-03-31: 13.7M
    the 31 Mar 2026 report24 earlier reportsnormal: 9.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Lobbying: Lobbying on a new issue became public on 20 Apr 2026

    Guardant Health lobbying on a new issue.

    New
    ['MED']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4686435

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  10. 20 Apr 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['MED']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4686435
  11. 11 Apr 2026Short interest and volume change

    had 13.7M shares sold short in the 31 Mar 2026 report, 1.7× the same report last year.

    Same report last year: 8.3M; its normal report is 9.2M.

    See the evidence
    This period
    13.7M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    9.2M
    Typical spread (median absolute deviation)
    791K
    How far from its usual level
    +3.8
    Same report last year
    8.3M
    History used
    2,724 days
    2025-03-31: 8.3M2025-04-15: 7.6M2025-04-30: 7.7M2025-05-15: 9.1M2025-05-30: 8.9M2025-06-13: 10.0M2025-06-30: 9.4M2025-07-15: 9.6M2025-07-31: 9.4M2025-08-15: 8.2M2025-08-29: 8.0M2025-09-15: 8.7M2025-09-30: 8.3M2025-10-15: 8.3M2025-10-31: 8.4M2025-11-14: 9.0M2025-11-28: 9.2M2025-12-15: 9.9M2025-12-31: 10.4M2026-01-15: 9.8M2026-01-30: 9.5M2026-02-13: 10.5M2026-02-27: 11.0M2026-03-13: 11.5M2026-03-31: 13.7M
    the 31 Mar 2026 report24 earlier reportsnormal: 9.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 19 Mar 2026Lobbying record

    GUARDANT HEALTH: lobbying engagement terminated (DC STRATEGISTS LLC)

  13. 30 Oct 2025Financials change

    spent $10.3M on capital projects in the quarter ended 30 Sep 2025, 2.5× the same quarter last year.

    Same quarter last year: $4.2M; its normal quarter is $4.8M.

    See the evidence
    This period
    $10.3M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $4.8M
    Typical spread (median absolute deviation)
    $786K
    How far from its usual level
    +4.8
    Same quarter last year
    $4.2M
    History used
    2,830 days
    2023-09-30: $2.4M2023-12-31: $4.1M2024-03-31: $6.9M2024-06-30: $5.1M2024-09-30: $4.2M2024-12-31: $18.9M2025-03-31: $4.5M2025-06-30: $5.6M2025-09-30: $10.3M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $4.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  14. 19 Oct 2025Lobbying record

    GUARDANT HEALTH: new lobbying registration (DC STRATEGISTS LLC) (dated 4 Sep 2025)

  15. 12 Oct 2025Lobbying record

    GUARDANT HEALTH, INC.: new lobbying registration (TODD STRATEGY GROUP) (dated 1 Apr 2025)

  16. 15 Sep 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 15 Sep 2025Filings record

    Director or officer change

  18. 21 Jul 2025Lobbying record

    GUARDANT HEALTH: lobbying engagement terminated (MANATT, PHELPS, AND PHILLIPS) (dated 30 Jun 2025)

  19. 15 May 2025Institutional holdings change

    saw 84 13F filers open a new position in the quarter ended 31 Mar 2025, 2.3× the same quarter last year.

    Same quarter last year: 37; its normal quarter is 39.

    See the evidence
    This period
    84 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    39
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +7.6
    Same quarter last year
    37
    History used
    2,282 days
    2023-03-31: 362023-06-30: 682023-09-30: 412023-12-31: 342024-03-31: 372024-06-30: 622024-09-30: 372024-12-31: 492025-03-31: 84
    the quarter ended 31 Mar 20258 earlier quartersnormal: 39

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  20. 25 Feb 2025Financials change

    spent $18.9M on capital projects in the quarter ended 31 Dec 2024, 4.6× the same quarter last year.

    Same quarter last year: $4.1M; its normal quarter is $5.8M.

    See the evidence
    This period
    $18.9M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $5.8M
    Typical spread (median absolute deviation)
    $1.7M
    How far from its usual level
    +5.3
    Same quarter last year
    $4.1M
    History used
    2,557 days
    2022-12-31: $10.0M2023-03-31: $7.5M2023-06-30: $6.5M2023-09-30: $2.4M2023-12-31: $4.1M2024-03-31: $6.9M2024-06-30: $5.1M2024-09-30: $4.2M2024-12-31: $18.9M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $5.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  21. 24 Oct 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 24 Oct 2024Filings record

    Director or officer change

  23. 18 Jul 2024Filings record

    Director or officer change

  24. 3 Jul 2024Lobbying record

    GUARDANT HEALTH, INC.: lobbying engagement terminated (INVARIANT LLC) (dated 1 Apr 2024)

  25. 31 May 2024Filings record

    Director or officer change

  26. 25 May 2024Short interest and volume change

    had 10.8M shares sold short in the 15 May 2024 report, 1.5× the same report last year.

    Same report last year: 7.1M; its normal report is 7.0M.

    See the evidence
    This period
    10.8M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    7.0M
    Typical spread (median absolute deviation)
    649K
    How far from its usual level
    +3.9
    Same report last year
    7.1M
    History used
    2,039 days
    2023-05-15: 7.1M2023-05-31: 6.9M2023-06-15: 7.6M2023-06-30: 8.6M2023-07-14: 8.2M2023-07-31: 7.5M2023-08-15: 6.8M2023-08-31: 7.0M2023-09-15: 6.9M2023-09-29: 7.0M2023-10-13: 7.4M2023-10-31: 7.0M2023-11-15: 6.3M2023-11-30: 5.7M2023-12-15: 5.5M2023-12-29: 5.2M2024-01-12: 5.3M2024-01-31: 5.5M2024-02-15: 5.7M2024-02-29: 7.1M2024-03-15: 7.8M2024-03-28: 7.6M2024-04-15: 9.6M2024-04-30: 10.2M2024-05-15: 10.8M
    the 15 May 2024 report24 earlier reportsnormal: 7.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 30 Apr 2024Lobbying record

    GUARDANT HEALTH: new lobbying registration (MANATT, PHELPS, AND PHILLIPS) (dated 19 Apr 2024)

  28. 22 Mar 2024Filings record

    Director or officer change

  29. 20 Mar 2024Insiders record

    Kalia Kumud (Chief Information Officer) bought 2,187 shares of GH ($38,972) (dated 19 Mar 2024)

  30. 1 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  31. 1 Feb 2024Filings record

    Director or officer change

  32. 3 Nov 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 3 Nov 2023Filings record

    Director or officer change

  34. 14 Jun 2023Insiders record

    Kalia Kumud (Chief Information Officer) bought 2,981 shares of GH ($97,494) (dated 13 Jun 2023)

  35. 10 Jun 2023Short interest and volume change

    had 6.9M shares sold short in the 31 May 2023 report, 1.7× the same report last year.

    Same report last year: 4.0M; its normal report is 4.4M.

    See the evidence
    This period
    6.9M (the 31 May 2023 report)
    Normal report (median of 24 earlier)
    4.4M
    Typical spread (median absolute deviation)
    478K
    How far from its usual level
    +3.6
    Same report last year
    4.0M
    History used
    1,689 days
    2022-05-31: 4.0M2022-06-15: 4.3M2022-06-30: 4.0M2022-07-15: 3.9M2022-07-29: 4.2M2022-08-15: 4.5M2022-08-31: 4.6M2022-09-15: 4.3M2022-09-30: 3.8M2022-10-14: 3.9M2022-10-31: 4.0M2022-11-15: 4.2M2022-11-30: 4.1M2022-12-15: 4.3M2022-12-30: 5.1M2023-01-13: 5.6M2023-01-31: 5.5M2023-02-15: 6.2M2023-02-28: 7.0M2023-03-15: 6.3M2023-03-31: 6.8M2023-04-14: 7.0M2023-04-28: 6.4M2023-05-15: 7.1M2023-05-31: 6.9M
    the 31 May 2023 report24 earlier reportsnormal: 4.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 25 May 2023Short interest and volume change

    had 7.1M shares sold short in the 15 May 2023 report, 2.1× the same report last year.

    Same report last year: 3.4M; its normal report is 4.3M.

    See the evidence
    This period
    7.1M (the 15 May 2023 report)
    Normal report (median of 24 earlier)
    4.3M
    Typical spread (median absolute deviation)
    389K
    How far from its usual level
    +4.8
    Same report last year
    3.4M
    History used
    1,673 days
    2022-05-13: 3.4M2022-05-31: 4.0M2022-06-15: 4.3M2022-06-30: 4.0M2022-07-15: 3.9M2022-07-29: 4.2M2022-08-15: 4.5M2022-08-31: 4.6M2022-09-15: 4.3M2022-09-30: 3.8M2022-10-14: 3.9M2022-10-31: 4.0M2022-11-15: 4.2M2022-11-30: 4.1M2022-12-15: 4.3M2022-12-30: 5.1M2023-01-13: 5.6M2023-01-31: 5.5M2023-02-15: 6.2M2023-02-28: 7.0M2023-03-15: 6.3M2023-03-31: 6.8M2023-04-14: 7.0M2023-04-28: 6.4M2023-05-15: 7.1M
    the 15 May 2023 report24 earlier reportsnormal: 4.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 10 May 2023Short interest and volume change

    had 6.4M shares sold short in the 28 Apr 2023 report, 1.6× the same report last year.

    Same report last year: 3.9M; its normal report is 4.3M.

    See the evidence
    This period
    6.4M (the 28 Apr 2023 report)
    Normal report (median of 24 earlier)
    4.3M
    Typical spread (median absolute deviation)
    370K
    How far from its usual level
    +3.8
    Same report last year
    3.9M
    History used
    1,656 days
    2022-04-29: 3.9M2022-05-13: 3.4M2022-05-31: 4.0M2022-06-15: 4.3M2022-06-30: 4.0M2022-07-15: 3.9M2022-07-29: 4.2M2022-08-15: 4.5M2022-08-31: 4.6M2022-09-15: 4.3M2022-09-30: 3.8M2022-10-14: 3.9M2022-10-31: 4.0M2022-11-15: 4.2M2022-11-30: 4.1M2022-12-15: 4.3M2022-12-30: 5.1M2023-01-13: 5.6M2023-01-31: 5.5M2023-02-15: 6.2M2023-02-28: 7.0M2023-03-15: 6.3M2023-03-31: 6.8M2023-04-14: 7.0M2023-04-28: 6.4M
    the 28 Apr 2023 report24 earlier reportsnormal: 4.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 8 May 2023Filings record

    Director or officer change

  39. 26 Apr 2023Short interest and volume change

    had 7.0M shares sold short in the 14 Apr 2023 report, 1.8× the same report last year.

    Same report last year: 3.8M; its normal report is 4.3M.

    See the evidence
    This period
    7.0M (the 14 Apr 2023 report)
    Normal report (median of 24 earlier)
    4.3M
    Typical spread (median absolute deviation)
    341K
    How far from its usual level
    +5.4
    Same report last year
    3.8M
    History used
    1,642 days
    2022-04-14: 3.8M2022-04-29: 3.9M2022-05-13: 3.4M2022-05-31: 4.0M2022-06-15: 4.3M2022-06-30: 4.0M2022-07-15: 3.9M2022-07-29: 4.2M2022-08-15: 4.5M2022-08-31: 4.6M2022-09-15: 4.3M2022-09-30: 3.8M2022-10-14: 3.9M2022-10-31: 4.0M2022-11-15: 4.2M2022-11-30: 4.1M2022-12-15: 4.3M2022-12-30: 5.1M2023-01-13: 5.6M2023-01-31: 5.5M2023-02-15: 6.2M2023-02-28: 7.0M2023-03-15: 6.3M2023-03-31: 6.8M2023-04-14: 7.0M
    the 14 Apr 2023 report24 earlier reportsnormal: 4.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 18 Apr 2023Lobbying record

    GUARDANT HEALTH, INC.: lobbying engagement terminated (POWERS PYLES SUTTER & VERVILLE, P.C.) (dated 2 Jan 2023)

Showing the newest 40 of 102 entries; narrow the window or the kind of data to see older ones.

Not listed: 361 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001576280
Ticker
GH
Domain
guardanthealth.com
Employer name
Guardant Health, Inc. (1 unverified)
Hq location
CA|PALO ALTO|94304 (1 unverified)
Lobbying client
guardant health
Name
Guardant Health, Inc.
Uei
ZTU8LL17Y3U7
Wikidata
Q53308751
Wikipedia
Guardant Health
  • DOL H-1B labor condition applications and PERM certifications967 data points7 Oct 2019 to 31 Aug 2026
  • Federal lobbying disclosures (LDA)16 records, 120 data points1 Dec 2016 to 30 Sep 2026
  • SEC Form 13F institutional holdings288 data points31 Dec 2018 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)132 records24 Mar 2016 to 16 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)644 data points31 Dec 2015 to 30 Oct 2026
  • SEC Form 4 insider transactions272 records, 868 data points14 Mar 2019 to 19 Nov 2026
  • FINRA short interest (twice monthly)578 data points15 Oct 2018 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4086 data points4 Oct 2018 to 20 Nov 2026
  • USASpending.gov federal awards12 data points5 Jul 2017 to 20 Sep 2021
  • Wikipedia pageviews2043 data points26 Feb 2021 to 21 Nov 2026